Table 3 HCC clinical Trials in Egypt
From: Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview
No. | Clinical trial number | Drug | Phase | Status |
|---|---|---|---|---|
1 | NCT02715492 | LMWH | Phase 3 | Not yet recruiting |
2 | NCT02771405 | •Drug: Sofosbuvir •Drug: Ribavirin •Drug: Simeprevir •Drug: daclatasvir •Drug: Ledipasvir | Phase 3 | Recruiting |
3 | NCT03551444 | Administration of DAA-based treatment | Phase 3 | Recruiting |
4 | NCT02971696 | •Drug: Sorafenib •Drug: Best Supportive care | Phase 3 | Completed |
5 | NCT03151213 | •Drug: Pregabalin 150 mg •Other: Placebo | Phase 3 | Recruiting |
6 | NCT02646137 | •Drug: Transarterial chemoembolization (TACE) •Procedure: Radiofrequency ablation combined with TACE •Procedure: Microwave ablation combined with TACE | Phase 3 | Recruiting |
7 | NCT01539018 | •Drug: Sorafenib •Drug: sorafenib plus tegafur-uracil | Phase 2 | Terminated |
8 | NCT02568748 | •Biological: CIK •Procedure: TACE | Phase 3 | Recruiting |
9 | NCT01655693 | •Drug: Doxorubicin •Drug: Best Standard of Care | Phase 3 | Active, not recruiting |
10 | NCT01009593 | •Drug: ABT-869/Linifanib •Drug: Sorafenib | Phase 3 | Terminated |